

Bladder Cancer

A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03330886 ML39853

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in Argentina.

Hoffmann-La Roche

Sponsor

Phase

NCT03330886 ML39853

Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No